DMPEN (4-demethylpenclomedine), the active metabolite of penclomedine [3,5-dichloro-4,6-dimethoxy-2-(trichloromethyl)pyridine], is a alkylation agent, and was demonstrated to have potent antitumor activity. DMPEN went Phase I clinical trials during 2000s. Currently no active clinical trials were reported. References: Morgan LR, Struck RF, Waud WR, LeBlanc B, Rodgers AH, Jursic BS. Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 Sep;64(4):829-35. Epub 2009 Mar 3. PubMed PMID: 19255760; PubMed Central PMCID: PMC2717391.

纯度：≥98%

CAS：176046-79-0